The Warnings Page

Serzone Sales Discontinued in Canada, $200 Million Class Action Ensues

Days after Health Canada publicized Bristol-Myers Squibb's (BMS) decision to discontinue sales of Serzone in Canada due to the antidepressant's association with liver damage, a Quebec man filed a $200 million class action suit against the drug company.

On Oct. 28, two days after Health Canada announced Serzone's withdrawal to the public, 36-year-old Steve Ledyit and his wife, Louise, initiated the suit against BMS and other companies that manufactured generic brands of the antidepressant. In the complaint, Steve Ledyit claimed that he received the drug four years ago and …